Unleashing the clinical power of T cells: CD19/CD3 bi-specific T cell engager (BiTE(R)) antibody construct blinatumomab as a potential therapy

Clinical value of pre-transplant minimal residual disease in childhood lymphoblastic leukaemia: the results of the French minimal residual disease-guided protocol

(2014) Virginie Gandemer et al.   BRITISH JOURNAL OF HAEMATOLOGY

New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape

(2014) Deepak Mittal et al.   CURRENT OPINION IN IMMUNOLOGY

Allogeneic transplantation as anticancer immunotherapy

(2014) Simrit Parmar et al.   CURRENT OPINION IN IMMUNOLOGY

Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab

(2014) P. Schlegel et al.   HAEMATOLOGICA

Clinical significance of minimal residual disease in young adults with standard-risk/Ph-negative precursor B-acute lymphoblastic leukemia: results of prospective study

(2014) Manal Salah-Eldin et al.   MEDICAL ONCOLOGY

Diffuse large B-cell lymphoma

(2013) Maurizio Martelli et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Non-Hodgkin’s B-cell lymphoma: Advances in molecular strategies targeting drug resistance

(2013) Steve A Maxwell et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

CAR T cells: driving the road from the laboratory to the clinic

(2013) Eleanor J. Cheadle et al.   IMMUNOLOGICAL REVIEWS

Relapsed childhood acute lymphoblastic leukaemia

(2013) Deepa Bhojwani et al.   LANCET ONCOLOGY

Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia

(2013) Shira Dinner et al.   LEUKEMIA & LYMPHOMA

Bispecific Antibodies and Trispecific Immunocytokines for Targeting the Immune System Against Cancer

(2012) Philippe Fournier et al.   BIODRUGS

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab

(2012) M. Klinger et al.   BLOOD

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

(2012) M. S. Topp et al.   BLOOD

Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies

(2012) Marcin Okroj et al.   CANCER TREATMENT REVIEWS

Blinatumomab: A historical perspective

(2012) Dirk Nagorsen et al.   PHARMACOLOGY & THERAPEUTICS

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

(2011) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

Bispecific Antibodies for Cancer Immunotherapy

(2010) Dafne Müller et al.   BIODRUGS

Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia

(2010) R Handgretinger et al.   LEUKEMIA

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)

(2009) R. Bassan et al.   BLOOD